A recombinant Modified Vaccinia virus Ankara expressing prME of tick-borne encephalitis virus affords mice full protection against TBEV infection

Tick-borne encephalitis virus (TBEV) is an important human pathogen that can cause a serious disease involving the central nervous system (tick-borne encephalitis, TBE). Although approved inactivated vaccines are available, the number of TBE cases is rising, and breakthrough infections in fully vacc...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 14; p. 1182963
Main Authors Kubinski, Mareike, Beicht, Jana, Zdora, Isabel, Biermann, Jeannine, Puff, Christina, Gerlach, Thomas, Tscherne, Alina, Baumgärtner, Wolfgang, Osterhaus, Albert D. M. E., Sutter, Gerd, Prajeeth, Chittappen Kandiyil, Rimmelzwaan, Guus F.
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 21.04.2023
Subjects
Animals
Antibodies, Neutralizing
Antibodies, Viral
Encephalitis Viruses, Tick-Borne - genetics
FSME-IMMUN
Humans
Immunology
Mice
MVA
protection
TBEV
vaccination
Vaccinia virus - genetics
Viral Vaccines
virus-neutralizing antibodies
TBEV
MVA
FSME-IMMUN
protection
T cells
virus-neutralizing antibodies
vaccination
Online AccessGet full text

Cover

More Information
Summary:Tick-borne encephalitis virus (TBEV) is an important human pathogen that can cause a serious disease involving the central nervous system (tick-borne encephalitis, TBE). Although approved inactivated vaccines are available, the number of TBE cases is rising, and breakthrough infections in fully vaccinated subjects have been reported in recent years. In the present study, we generated and characterized a recombinant Modified Vaccinia virus Ankara (MVA) for the delivery of the pre-membrane (prM) and envelope (E) proteins of TBEV (MVA-prME). MVA-prME was tested in mice in comparison with a licensed vaccine FSME-IMMUN® and proved to be highly immunogenic and afforded full protection against challenge infection with TBEV. Our data indicate that MVA-prME holds promise as an improved next-generation vaccine for the prevention of TBE.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Salman Sadullah Usmani, Albert Einstein College of Medicine, United States
Reviewed by: George William Carnell, University of Cambridge, United Kingdom; Wei Ye, Air Force Medical University, China
These authors have contributed equally to this work and share first authorship
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1182963